Good afternoon, and welcome to CloudMD's Q1 earnings conference call and webinar. My name is Joelle, and I will be your conference facilitator today. As a reminder, this conference call is being recorded. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. The company invites its covering analysts to ask questions during this conference call by pressing star, then the number one key on their telephone keypad. If a covering analyst would like to withdraw their question, press the pound key. Thank you. It is now my pleasure to turn the call over to Julia Becker, the VP of Investor Relations, with opening remarks. Perfect. Thank you, Joelle. Good afternoon, everyone. Thank you so much for joining us today, May 27th, 2021, for our first quarter 2021 earnings conference call and webinar. We'll start the call with a summary from our Chief Executive Officer, Dr. Essam Hamza, followed by our Chief Health Innovation Officer and Global Head Enterprise Health Solutions, Karen Adams, who will provide further commentary on our Enterprise Health Solutions division, or as we often refer to it, our EHS division. Our Chief Financial Officer, Dan Lee, will recap the company's first quarter 2021 financial results before opening up for a question and answer period from the analysts. A friendly reminder to everyone that today's discussion contains forward-looking information, which involves inherent risks and uncertainties and other factors that could cause actual results to differ materially from management's current expectations. Forward-looking statements should not be read as assurance of future performance or results. The risks related to the forward-looking information are described in the company's annual information form for the period ended December 31st, 2020, which is available on SEDAR under the company's profile, and in the company's management discussion and analysis for the year ended December 31st, 2020, and the quarter ended March 31st, 2021, both of which are also available on our profile on SEDAR. We encourage listeners to review our disclosure in the context of the forward-looking information you may hear today during this earnings call. Investors are also cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this call. The company disclaims any intention or obligation, except to the extent required by law, to update and revise any forward-looking statements as a result of new information, future events, or for any other reason. With that done, it is my pleasure to turn the call over to Dr. Essam Hamza, CEO of CloudMD. Essam, the floor is yours. Thank you, Julia, and good afternoon, and thank you for joining us for our first quarter earnings call and webinar. I'm very excited to share the details of our record Q1 2021 operational and financial results. CloudMD has made solid strategic and financial progress in the first three months of 2021 following a transformational year in 2020, where we built a foundation that positions us to be leaders in the delivery of healthcare. In the middle of a global pandemic, we were not only able to keep our operations running, but also build consistent growth across our entire business. Through this transition, our mission and vision have never changed. CloudMD is a health tech company revolutionizing the delivery of healthcare through a patient-focused, whole-person approach to care. By leveraging technology, we are building a complete and connected healthcare ecosystem that addresses all points of a patient's care, including primary care, virtual care, mental health support, access to specialists, health navigation, and education. This proprietary platform underpins our organic growth strategy, which we continue to see across all lines of our business. The company was built on three foundational pillars that continue to serve us well. First, patient-centric, longitudinal healthcare is the future and results in better access to care and improved outcomes. Secondly, we are led by a team of medical professionals, doctors, and industry experts that understand the pain points of the fractured medical system and share the vision of team-based whole-person care. Finally, in order to execute on this vision and build a connected ecosystem, we must own our own technology solutions. Technology is the great equalizer that allows us to provide better access to healthcare and connect the siloed aspects throughout healthcare navigation. We are delighted with our Q1 2021 operating and financial performance. We reported record revenue of CAD 8.8 million, a 187% increase from Q1 2020 and 51% increase from Q4 2020, largely attributable to strategic M&A and organic growth. In the quarter, we closed five acquisitions, adding CAD 13 million in annual revenue, and we established our transformational Enterprise Health Solutions division, which Karen will speak to shortly. In addition, the operating businesses are collaborating to leverage our assets, creating the whole-person healthcare ecosystem. All of our acquisitions are high-growth, accretive, and synergistic with cross-selling opportunities to drive further organic growth. In February, we closed an oversubscribed CAD 58 million bought deal financing, which provides us with strategic capital to deploy on mergers and acquisitions. We are well-funded with almost CAD 100 million in the bank. In addition to being well-funded, we have access to debt financing and are looking at options to fund our future M&A activities while conserving cash and equity. We view our businesses into three categories. It's important to note these categories are not siloed, and they capitalize on each other's capabilities and are synergistic with each other. We categorize our businesses into clinic services and pharmacies, digital services, and finally, Enterprise Health Solutions. We are proud to announce that we achieved growth across all divisions in the first quarter and expect to see continued growth throughout 2021. Our clinics and pharmacies network consists of 14 hybrid clinics, two pharmacies, and approximately 100 practitioners servicing over 500,000 patients. Our hybrid clinics include both in-person and telemedicine visits, which capture the full revenue potential from a patient. Over the last year, we've seen a significant increase in telemedicine adoption by our clinic network, and we have experienced a 20% increase in patient visits in every quarter since the launch of our CloudMD app in February 2020. Our telemedicine service complements our other businesses, including the Enterprise Health Solutions division, and we are focused on providing longitudinal whole-person care by integrating this service with our other offerings. Our health tech solutions collectively make up our digital services category. In Q1, we announced the acquisition of VisionPros, adding over CAD 35 million in annual revenue. At the end of the quarter, we closed the acquisition of IDYA4, the technology platform used to connect our ecosystem. Since we announced the acquisition in December 2020, IDYA4 has recognized over CAD 1.5 million in contract wins. We expect significant organic growth throughout the year. The Enterprise Health Solutions was launched in Q4 2020. Along with Re:Function and Assessment and Rehabilitation Clinic Network, it will represent approximately 44% of the company's CAD 120 million annualized revenue run rate. We launched this division with a focus on client needs of cost optimization, targeted clinical solutions, and that were outcome-based, supporting access to care for individuals with health and wellbeing concerns. I'll now pass it over to Karen Adams to give an update on the Enterprise Health Solutions division. Thank you, Essam. This division was founded on targeted acquisitions that had reoccurring revenue and all with strong client bases. Our differentiator is that we created a market-leading position through integrating our clinically evidence-based capabilities and nurse care navigator platform for the seamless delivery of mental and physical health to individuals. This access and quality of care creates a better user experience and optimizes costs for employers while delivering health outcomes. We continue to make progress on executing our strategic plan while making deliberate investments in enhancing our capabilities. I am extremely proud of the team's effort in growing our core business capabilities within Enterprise Health Solutions, EHS, and the adoption of our integrated offerings launched in Q1. Our Q1 results fully reflect the effect of last year's acquisitions of iMD, Re:Function, and Snapclarity. Subsequently, in Q1, we completed the following acquisitions. HumanaCare, a national employee and family assistance program, or commonly referred to as EFAP, a mental health solutions provider based in Ontario. This acquisition expands our ability to service the employer mental health market need, expanding breadth and depth of services to address mental health. HumanaCare has forged solid long-term client relationships through clients and third-party brokers using innovative solutions. Medical Confidence, a national Canadian leader in healthcare navigation. Medical Confidence has built a strong reputation for innovative solutions in managing health issues of those on disability through outcome-driven care pathways and solid long-term relationships with clients. This acquisition enables us to leverage healthcare navigation as foundational to our ecosystem, providing a strong value proposition to insurers, brokers, and organizations to optimize health outcomes and costs. These companies' financial results are only partially reflected in our Q1 results. We have seen a strong adoption of our strategy through organic growth, which was slightly above 10%, resulting from a new distribution partnership and a strong sales pipeline. Including Assessment and Rehabilitation Clinical Network, EHS revenue was CAD 3.1 million in Q1. This was driven by innovation, technology-enabled products, and reoccurring revenue. In Q1, we launched a change management office to execute our integration initiatives to better focus on the user experience and manage priorities. This has resulted in increased revenue as well as gross margin and EBITDA expansion through several initiatives, including consolidation of our back office platforms for iMD, which is our educational resources. Snapclarity, our mental health online assessment tool, and HumanaCare to strengthen the company's position as a leader in mental health support solutions. We initiated the first phase of integration with shared services for recently acquired companies. Additionally, we executed on cost synergies near the end of the quarter and will realize CAD 500,000 in annual cost savings going forward. Second, expansion enhancement of our client acquisition and servicing team. Third, the introduction of a VP of Product Management who identified workflow solutions that improves the user experience. I will now touch on some of the business highlights of Q1 as we focus on creating a leading health navigation service in the market space. A key part of our growth strategy is our integrated health navigation platform. In Q1, we focused on the implementation of our health navigation platform with a premier 11,000 life group. We have a strong pipeline for the integrated offering and have completed numerous proposals for clients interested in this specific platform to connect wellbeing for mental and physical health while optimizing their group benefits plans. In addition, we earned contracts with three insurers for our healthcare disability navigation product that will be leveraging the platform as they reduce disability days and focus on return to work. These contracts will be implemented in the coming quarters. In our mental health support, which includes EFAP, we added many new contracts to our platform and made our evidence-based mental health assessment tool through Snapclarity available to EFAP customers with an adoption rate of 45% in Q1. We continue to see momentum and new lives added through broker relationships who market our services to their client base. We have several proposals for distribution partnerships. We launched the first mental health coaching program with assessment, triage, and navigation, as well as a virtual trauma support program. Finally, in our assessment and rehabilitation capabilities, we earned new contracts with government agencies and have expanded to new capabilities in psychological assessments for prevention and early intervention. We also implemented a new approach to assessments for psychological impairments with a major insurer in providing assessment and treatment for claimants. We are focused on growth, but we have identified further cost-saving synergies as we continue to integrate capabilities across all of CloudMD, creating margin and EBITDA expansion while providing access to quality clinical care. Client satisfaction rates are trending above our internal targets, solidifying our confidence and continued growth of our strategy in the coming months. We launched our services in the United States and are recipients of a new distribution partnership with a national group benefits provider who will be implemented in the coming quarters. Our four pillars of performance focus on, number one, continued growth of solid recurring revenue in the core businesses. Number two, actively manage integration of the entities that are critical to our product offering and EBITDA growth. Number three, continued development of our technology utilizing the recently acquired health and wellness platform of IDYA4 to enable health navigation and connection of acquired companies' associated capabilities. Number four, U.S. expansion through leveraging our health and wellness platform and health capabilities. Our clients have worked with us to create a market-leading solution that transforms the way health benefits are delivered to employees, resulting in reduced disability days, improved access to care, and medical-based navigators who are able to respond and adjust treatment. We continue to focus on access and quality of care through the development of our ecosystem platform, connecting both mental and physical health programs, providing one seamless delivery for mental, physical, and specialist support. I will now turn it over to Daniel Lee, our CFO, for the financial update. Thank you, Karen. As you saw that Karen touched on, it was a very good quarter for the business. We are very excited by our Q1 2021 results and the framework we have built for scale and growth. I will now walk through our fiscal 2021 first quarter results. For the quarter, total revenue was CAD 8.8 million, compared to CAD 5.8 million in Q4 2020 and CAD 3.1 million in Q1 2020. The increase is primarily attributable to acquisition growth with five acquisitions completed in the quarter and 11 acquisitions completed in the last 12 months. Excluding the impact of Q1 business acquisitions, the company achieved organic growth from its existing businesses. While the majority of the company's historical revenues were derived from clinic services and pharmacies, we expect Enterprise Health Solutions and digital services to comprise of over 80% of total revenues starting in Q3 due to the company's recently completed and announced acquisitions. For the quarter, gross margin was 41% in Q1 2021 compared to 40% in Q4 2020 and 37% in Q1 2020. The increase was primarily attributable to revenue mix, where higher-margin revenues from Enterprise Health Solutions and digital services made up a stronger percentage of overall revenues. Given the completed and announced acquisitions, the company does expect its future gross margin to settle in the 35% range. While both Rxi and VisionPros are profitable, they do operate in high volume, lower margin businesses, which affect our overall gross margin. For the quarter, adjusted EBITDA was a loss of CAD 1.5 million in Q1 2021 compared to a loss of CAD 1.5 million in Q4 2020 and a loss of CAD 800,000 in Q1 2020. The company expects to improve its adjusted EBITDA performance in the coming quarters, which includes the profitable businesses we acquired in the last 12 months and the cost synergies we've started to realize near the end of Q1. Turning now to the balance sheet. Cash and cash equivalents were CAD 99 million at March 31st, 2021, compared to CAD 60 million at December 31st, 2020. In Q1 2021, the company raised gross proceeds of CAD 58 million in a bought deal financing in March 2021. The company paid CAD 13 million for five acquisitions, net of cash acquired in the quarter. Currently, the company has a cash and cash equivalent position of approximately CAD 95 million, and we anticipate the acquisitions of VisionPros and Oncidium to close sometime in June 2021. Lastly, given our Q1 2021 financial performance, we reiterate that CloudMD's annualized revenue run rate exceeds CAD 120 million. We calculate our annualized revenue run rate based on a combination of, one, the last 12 months of revenues from our existing businesses, and two, 2020 annualized revenue run rate for acquisitions completed since October 2020 and acquisitions announced but not yet closed, including VisionPros and Oncidium. CloudMD's annualized revenue run rate is intended to serve as the baseline for the business. This baseline does not include the organic growth that we're currently witnessing within the Enterprise Health Solutions division or post-acquisition cross-sell synergies we're seeing in our other businesses, which serves as an upside to our numbers. We are well-positioned for growth, and this is why we're very excited about the future of CloudMD. With that said, I'd like to turn the call back to Essam for closing remarks of a very successful quarter. Thank you, Daniel. Everyone at CloudMD is proud of the work we are doing to transform the delivery of healthcare and the momentum we are seeing in the market. I would personally like to take a moment to thank our incredible team at CloudMD for their hard work and dedication to our vision. The company is well-funded to execute on its strategy with a strong financial position and access to capital. Our mission is to provide better access and improve healthcare outcomes to patients globally, and we are very excited about the growth of CloudMD in the coming quarters and years. I thank our shareholders and analysts for their continued support. With that, I'll ask the operator to open up for calls. Thank you. As a reminder, to ask a question you will need to press star one on your telephone. To withdraw your question press the pound key. Please standby while we compile the Q&A roster. Our first question comes from Doug Taylor with Canaccord Genuity. Yeah. Thank you, and good evening. In the past, you provided a couple data points that helped us think about the organic growth post-acquisition of some of the elements, mostly within the EHS segment. I know, Karen, you walked through a number of areas of success, but I wonder if you could provide us with or offer up any sort of quantitative numbers that help us think about the organic growth that you are seeing now to layer on top of that baseline CAD 120 million revenue that you speak to. Dan, do you want me to take that? I guess, w hy don't I answer that first, and Karen, feel free to add more comments to that. Doug, we did announce back in March about CAD 5 million of new contract wins within Enterprise. Within Q1, we did realize about CAD 250,000 revenues coming from those contracts. In Karen's prepared remarks, she did mention that we did experience a 10% organic growth within Enterprise. Basically how that number is derived is taking our 2020 EHS revenue run rate. When we had acquired those companies, we had a baseline, and so the organic growth coming from these contract wins, we're adding about, call it about CAD 1.5 million of revenues to our 2021 numbers. Just to answer your question, we have CAD 120 million revenue run rate, and that increases by about CAD 1.5 million specifically for 2021. Okay. No, that's helpful in helping us think about that. You mentioned the cost synergies that you've achieved since. I believe last time you talked to about CAD 500,000. Can you just talk to what you've recognized out of that and whether CAD 500,000 is still the number that you've confirmed that that's the number that you've still seen or have you uncovered any more in addition to that? Yeah. I'll start just in terms of talking about Q1, Doug, and Karen can certainly provide more color. In terms of Q1, we did execute those synergies near the end of the quarter, and so there hasn't been a lot of- Okay. Savings baked into our Q1 numbers. We will see call it CAD 500,000 annualized run rate in our model going forward starting in Q2. Yeah. The only other piece I would add is we continue to look for the synergies through the change management office and identifying as new acquisitions come on board. Shared services and integration of capabilities is a focus for us around the future identification of synergies go forward. It's an active process and now part of our onboarding of acquisitions. Right. We'll obviously look for more once those remaining acquisitions close. I believe the guidance you provided here was for positive EBITDA now in the second half of the year. I just want to understand, should I be reading anything into that versus the prior Q3? Is there a distinction there or am I just overthinking that? Yeah. In terms of EBITDA, we are expected to be EBITDA positive. We are getting closer to EBITDA positive, Doug. With Oncidium and VisionPros being completed sometime in the next month or so, we do expect for us to be EBITDA positive on the back end. In addition to the acquisitions where we will be realizing the cost synergies that we've already executed. Also, we're identifying more savings down the road, so that'll certainly help us on the back end. So just to confirm- I don't know if that answered your question or not. Well, I just want to confirm there's really no change in your timetable or expectation there. It was just a change in the language that I'm reading too much into. Is that fair to say? Yeah, there's no change in our- Yeah. There's no change in our y eah. Well, I just wanted to clarify. I've had questions about it already. Last question from me, and I guess I'll put this one to both you, Essam and Karen. I think in the last time you reported, and since we kind of signaled a period where you're looking to digest all these targeted acquisitions that you've executed on in the last year, would you say that's still the stance right now while you're awaiting the close of the remaining couple acquisitions, or are you still open to additional activity here in the near term? Maybe I'll start there, Karen. We are always open and do have a strong pipeline still of potential acquisitions that follow the mandates that we talked about earlier when I mentioned that are profitable growth companies that are synergistic with what we do. The difference now that I would say, Doug, honestly, is that we've built the foundation already, and we're able to now go and find really good value that can tuck into that infrastructure we've already built. I think there's going to be even greater opportunity to find additional add-in to what we do already. We don't need to find the big puzzle pieces because we've already created those acquisitions already and put them together. We are going to be adding other M&A opportunities over the next few quarters. Okay. Thank you for clarifying, and I'll pass the line. Thank you. Our next question will come from Rob Goff with Echelon. Please go ahead. Good afternoon, and thank you for taking my question. I'll actually have two questions, if I may. The first one would be on VisionPros. If you could perhaps give us an update on what you are seeing there in terms of momentum on the subscription front and excuse me, anything around its new vision test. The other question was on the EHS side, where Karen mentioned launching into the U.S. and adding distribution capabilities. If you could perhaps elaborate on that, it would be appreciated. Thanks, Rob. With regard to VisionPros, we're working on closing it right now. Over the next month here, as Dan referred to, we should have that closed and announced to the market. At that time, I think we'll update the market on what we're seeing and our expectations with VisionPros. Until then, we're probably not going to give any guidance on what we're seeing before we close it. If that's okay, Rob. Cool. Understand. Yeah. I'll have Karen maybe expand on our U.S. expansion here. Yeah. We have put somebody in place who is in charge of our growth strategy for the U.S. for our Enterprise Health Solutions, specifically around the mental health. They have a salesperson reporting to them, and they are completing proposals and have been successful in securing a distribution partnership with a benefits broker in the U.S. We will be looking to roll that out over the next couple of quarters with that specific distribution partner. Perhaps in terms of your distribution partner, would you be targeting large enterprise, mid-enterprise, or any sort of target profiles you could provide? Yeah, I think with this specific distribution partner, I'd say we're looking in the mid-market, which is still large in the U.S., as you know. We are looking at the mid-market right now, and using the mental health assessment and the navigation platform becomes relatively easy for us to deliver across the U.S. We're very excited about earning this opportunity with this broker. Very good. Thank you. Thank you. Thank you. Our next question comes from Gabriel Leung with Beacon Securities. Your line is now open. Afternoon, thanks for taking my questions. A couple of things. First, just curious if you guys are able to provide an update on the, I guess, the large corporate client that was onboarded on the Enterprise side, I guess, a couple of months ago, whether you have an update on how things are progressing there? We launched that client, and the client satisfaction is very high. It's very early to tell the outcomes because the client launched it at the end of April, beginning of May. We're still in early days. Most of the first quarter was in the implementation of that large client. Got you. What are some of the metrics that you or your client will be reviewing to gauge whether the pilot is a success or not? That's a great question. The first thing is access. The number of people who access the program is our first metric. They have a population base. We're looking for access. So far, it is the most successful program they've launched. Those are their words. We'll be looking at accesses. We'll also be looking at the people who utilize the resources. We do have a number of online resources, both through iMD, which is our educational resource company, and through Snapclarity. We'll be gauging those. The third is people who are in need of treatment and the success ratio around the treatment. Those will be longer-term metrics just by the nature of the number of sessions required for people to actually get help through mental health. The short-term metrics that we're really focused on is access, satisfaction with the resources, and then access to care if that makes sense. Got you. Then just staying on Enterprise for a minute here. As I think about growth going forward, I think about pipeline of new potential customers. I also think about increasing utilization by members themselves. I'm curious if you can talk a little bit about both. What are you seeing in terms of pipeline opportunities, number one? Number two is, I guess, on the EAP side, with HumanaCare, it's obviously early, but whether you've seen any evidence of increased utilization by members via some of the additional services that you can now offer. It's early days. I always have to remind myself that it's early days. We did see in the first quarter an increase of 17% utilization of EFAP services. What I think you'll see in the coming months, one of the metrics that we are starting to measure is the number of customers who utilize more than one services. As I mentioned in my remarks, we have through the integration team structured a cross-sell team. The salespeople have all been trained on the product and are now in the process of taking to their clients the combined product offering. That is what we're measuring and filling through our pipeline at this point. Got you. I guess the other thing just that I should mention that's important, it just occurred to me as you said it. The EFAP really has in the first quarter, I think when you look at the number of new lives that they added to the platform and the utilization, they have done an incredibly good job in the first quarter. We are up over Q4 as far as utilization, and most of that is attributed to the distribution partnership that they were able to secure in Q4 that launched in January of Q1. That really is where we saw the uptick on the number of lives added to the platform, which was just over 6,000 lives. Got you. Actually just on that front, going forward as Oncidium is brought into the mix, and as the EAP practice gets bigger, to help us model, I guess, do you think CloudMD will be in a position to provide metrics around members and sort of PMPM and fees and things like that? Do you think that'll be coming down the road? Yeah. We'll just have to look at that because the Oncidium business is in a price per employee per month model. The Oncidium model is more of a case price. They do medical management, case management, which is a case price, and then, of course, the EFAP is a price per employee per month. I think it would be fair to assume that we will be in a position to talk about cross-sell and our ability to take the EFAP product and market it to the Oncidium clients to create that market-leading product. We believe we have a market-leading product that those customers are going to want. We'll be in a position to talk about that at that point as those quarters roll out. Got you. No, that's helpful. Maybe one last question. Sure. Just as I think about growth going forward, is there sort of a target bookings number that management is aiming towards achieving, whether calendar 2021 or calendar 2022? Now that you're very close to getting everything onboarded, is there a number that you guys thought about or are sort of targeting at this point? Daniel, did you want to take that? Sure. Gabe, we do have internal meetings about this. We're not, I guess, at this time, just ready to share that information. We do analyze our business and review not only just the financials, but also all key KPIs, internal targets, et cetera. We'll certainly take it under advisement in terms of just additional information to share with the analysts going forward. Got you. Appreciate the feedback. Thank you. Thank you. Our next question comes from Nick Agostino with Laurentian Bank Securities. Your line is now open. Yes. Good afternoon. I guess my first question, I just want to make sure I heard clearly and then ask the question on the back of that is, Essam, did you say you've seen 20% increase in patient visits every quarter, I guess, since you launched the virtual care program? If that number being the case, can you maybe provide some clarity around what the split is between virtual, the use of your telehealth program, versus in-person into your clinics? Then adding to that same question, how much repeat business are you guys seeing on the whole virtual care side of it? Thanks, Nick. You're right. The number I think I did quote was 20%, I believe, quarter-over-quarter. That is with regards to the CloudMD app. Let me step back for a second and describe what we have and what we built. We have the clinics, our clinics that are brick and mortar that we've converted into that hybrid clinic. When COVID hit, a lot of clinics around the country and around the world had to shut down, and unless you had a way to reach out to the patients, a lot of them lost revenue. We didn't. We were able to close the physical door and open up our virtual doors immediately, and those doctors in our network that are seeing patients for our company, we're continuing to see them through our virtual platform. That's seamless, basically. The same platform they use to see a patient in person is the same platform that they can use to see the patient virtually, the same chart and everything else. Our own doctors within our network were able to turn on virtual care, for the most part, 100% of their visits early on, and it's still a great majority right now are virtual, basically for those doctors seeing their own patients. On top of that, we launched our CloudMD app in B.C. and Ontario, and that CloudMD app was for patients that didn't have a doctor or didn't have an access to doctor. It was amazing when we first launched it. Obviously, with COVID, it allowed a lot of patients to see a doctor when they had no other options and they were in distress and so on. They're very grateful, and we had great success with it. On top of it, we've seen 20% quarter-over-quarter growth in that, and those are repeat customers as well. They're coming in, they're seeing our doctors. We don't only have family doctors that are seeing these patients. We have nurses, we have mental health professionals and so on that can help. We can send them for blood work. We can send them for referrals. We follow up with them. We can address their concerns. We reach out to them and their families and so on. We provide full care for them, not just episodic care. That's the growth in the number of visits through the app is what we were referring to there, and it continues to grow going forward. Why I bring this up, though, is that we've created this full platform and this ecosystem that is going to continue even post-COVID, because it is providing that full ecosystem of care to those patients. It's full care for all their needs, basically, and it also has the ability to cross into and support our Enterprise Health Solutions as well. That's the reason that we built it the way we built it. It's sustainable, it's profitable, and it's growing, not only as a standalone, but as integrated with our EHS and our other divisions as well. That's what we were referring to, if that helps. Yeah. Okay, great. Thank you. My second question is, I believe you closed five acquisitions in the quarter itself, if I recall reading correctly. My question is, now that you've had these companies as part of the CloudMD umbrella, you're able to look under the hood, any surprises upwards or downwards and specifically on revenue? In other words, is the revenue you're generating off of each and every one of those acquisitions that you closed in line with what your expectations that you've provided? Maybe I'll start with that, and then I can hand it over to Karen or Dan. Yes, the reason we bought, remember, these were companies we strategically went out and pursued. They were not for sale. They joined us because they share the same kind of vision in where healthcare is going. The great thing about it is they're already growth companies, they're already profitable, and we're able to add fuel to what they're offering immediately and have the ability to provide our network of patients and providers to what they already had. The cross-selling has helped every one of our companies that we brought on so far. We did make reference to it in an earlier press release in the quarter, if you remember mentioning the fact that as of the first two, three months of that quarter in the Enterprise Health Solutions, that they were able to recognize CAD 5 million of new contracts just early on, just from since we announced them to when we closed it to the time that we released that press release. Maybe, Karen, you can refer a little bit to that. Before you do, we also mentioned IDYA4 in the same realm as well, saying that they were awarded another CAD 1.5 million at that time that we announced that close. Yeah. I'd just say a couple things, Nick, to add to that. Yes, we are seeing organic growth that is, I would say, in line with our expectations because, as Essam mentioned, these were targeted strategic. They were known to us. I understand their capabilities very well. Putting them together in a way that fit with a strong client base made sense. The second piece, and I have to remind myself that these acquisitions, being Q1, Q2, or Q1 being January, we've done some incredible work around the synergies. These synergies, I think, are coming together naturally because of the understanding of the people who work within these acquisitions, the importance of putting these products together. They're motivated to be part of a synergistic exercise, as opposed to when you do acquisitions, sometimes the synergistic opportunities have to be forced, and you're looking for rationales for people. People are gravitating quite easily. When we look at the acquisitions from Q4, and we look at the ones we're doing now, including IDYA4, the traction to come together is very easy. The other piece I think is important to acknowledge is we are leveraging capabilities outside of EHS, meaning, we have had Snapclarity integrated into the virtual care product. We are using the digital services and will be using some of the acquisitions we've talked about going forward that might be outside of EHS as capabilities that will be connected in the ecosystem. I'm pretty proud of the team that we have been able to not only get the CAD 1.5 million in organic growth, but also the synergies that we have been able to recognize in the team working forward. The clients are coming to us and asking for proposals for these integrated offerings, which is accelerating the need for the synergy. Where I sit, I'm very pleased, and I would say we are right where we expected to be with the traction. I would say probably maybe even a little ahead of plan as far as the activity base goes, getting us to move forward with the synergies. I'm very pleased. Okay. Thank you. That was all. As there are no further questions, this concludes today's conference call. Thank you for participating. You may now disconnect.